Abstract
Hepatitis C is one of the leading indications for liver transplantation. Recipients can expect at least a short-term survival equivalent to other indications for liver transplantation. However, the rates of cirrhosis and decompensation development is substantially faster than those rates seen in non-transplant setting. Advances in antiviral therapy are now associated with a sustained virological response of 20% with combination antiviral with interferon and ribavirin. Higher response rates are expected with utilizing pegylated interferon.
Original language | English (US) |
---|---|
Pages (from-to) | 479-489 |
Number of pages | 11 |
Journal | Minerva Chirurgica |
Volume | 58 |
Issue number | 4 |
State | Published - Aug 2003 |
Keywords
- Antiviral agents
- Hepatitis C
- Liver cirrhosis
- Liver transplantation
ASJC Scopus subject areas
- Surgery